In this paper, systematic reviews, randomized controlled trials and other relevant studies on surgical and adjuvant therapy following operative therapy in renal cancer were identified by searching the Guidelines International Network, ACP Journal Club, the Cochrane Library （Issue 3, 2005 ） , MEDLINE, EMBASE and CBMdisc （ from 1996 to Sept. 2005）. In operative therapy, we found no study comparing operative therapy with no treatment or adjuvant therapy alone; A meta-analysis of cytoreductive nephrectomy in patients with metastatic renal cancer showed adjuvant therapy following nephrectomy was more effective than adjuvant therapy alone; a review comparing radical nephrectomy with nephron-sparing surgery in small-volume renal tumors found similar effectiveness between the two procedures. In the adjuvant therapy following nephrectomy, ten RCTs found adjuvant cytokine therapy （Interferon and Interleukin-2 ） and 5-FU not effective in the adjuvant setting, and could increase adverse reaction; Four RCTs found adjuvant vaccine therapy effective in the adjuvant setting with only a few side effects.
目的 通過檢測人睪丸生殖細胞腫瘤中的Skp2蛋白質異常表達,探討相關意義。 方法 應用S-P免疫組織化學法檢測睪丸生殖細胞腫瘤，正常睪丸組織和慢性睪丸炎組織中Skp2的表達。 結果 睪丸生殖細胞腫瘤中Skp2陽性表達率為74.5%，正常睪丸組織中Skp2陽性表達率為20.0%，在慢性睪丸炎組織中Skp2陽性表達率為40.0%，在3種不同睪丸組織中表達差異有統計學意義（P＜0.05）；Skp2表達與不同組織學類型的睪丸生殖細胞腫瘤無相關性（P＞0.05）；隨著臨床分期的增高，睪丸生殖細胞腫瘤中的Skp2表達增多，差異無統計學意義（P＞0.05）。 結論 在人睪丸生殖細胞腫瘤中的Skp2高表達，提示細胞周期的異常調控在睪丸生殖細胞腫瘤的發生、分化中起著重要的作用。